glp-1 obesity drug news october 2025 today GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 From evidence to action: WHO

GLP-1RA should not be used in patients with a history of acute or chronic pancreatitis and therapy should be stopped immediately if there are clinical signs and symptoms of acute pancreatitis

Saxenda (liraglutide) Saxenda (liraglutide) is FDA-approved for chronic weight management

at least 50% of patients receiving 10 or 15 mg of tirzepatide per week achieved a weight loss of 20% and more 6,59,60,61,62 .Tirzepatide was also superior to semaglutide at reducing levels of glycated hemoglobin 63

I'm setting myself up for success with that first bite, rather than eating those potatoes and iced coffee that are going to have me crashing by 12 p.m

Research and development of safe and effective anti-obesity pharmacotherapies is urgently needed considering the current obesity epidemic